HUP0500997A2 - Chemically-modified human growth hormone conjugates - Google Patents

Chemically-modified human growth hormone conjugates

Info

Publication number
HUP0500997A2
HUP0500997A2 HU0500997A HUP0500997A HUP0500997A2 HU P0500997 A2 HUP0500997 A2 HU P0500997A2 HU 0500997 A HU0500997 A HU 0500997A HU P0500997 A HUP0500997 A HU P0500997A HU P0500997 A2 HUP0500997 A2 HU P0500997A2
Authority
HU
Hungary
Prior art keywords
chemically
growth hormone
human growth
modified human
hormone conjugates
Prior art date
Application number
HU0500997A
Other languages
English (en)
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of HUP0500997A2 publication Critical patent/HUP0500997A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HU0500997A 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates HUP0500997A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
HUP0500997A2 true HUP0500997A2 (en) 2007-11-28

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500997A HUP0500997A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (hu)
JP (2) JP2005525302A (hu)
KR (2) KR20050044858A (hu)
CN (1) CN1608079A (hu)
AP (1) AP2004003050A0 (hu)
AU (1) AU2002356990A1 (hu)
BR (1) BR0214451A (hu)
CA (1) CA2467731A1 (hu)
CO (1) CO5580794A2 (hu)
EA (2) EA200700431A1 (hu)
EC (1) ECSP045114A (hu)
GE (1) GEP20063860B (hu)
HR (1) HRP20040448A2 (hu)
HU (1) HUP0500997A2 (hu)
IL (1) IL162031A0 (hu)
IS (1) IS7268A (hu)
MA (1) MA27544A1 (hu)
MX (1) MXPA04004809A (hu)
NO (1) NO20042182L (hu)
OA (1) OA13063A (hu)
PL (1) PL374354A1 (hu)
RS (1) RS53104A (hu)
TN (1) TNSN04090A1 (hu)
WO (1) WO2003044056A2 (hu)
ZA (1) ZA200403907B (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
ME00239B (me) * 2002-01-18 2011-05-10 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
ES2897470T3 (es) 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
CN100580087C (zh) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2368579A1 (en) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
CN103290084A (zh) * 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
CN103690936A (zh) * 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
EP1877439B1 (en) 2005-04-18 2011-02-09 Novo Nordisk A/S Il-21 variants
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
AU2006311568B2 (en) 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
US20080317670A1 (en) 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
KR20100014215A (ko) 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2720306C (en) 2008-04-03 2016-03-15 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
KR101533757B1 (ko) * 2008-07-31 2015-07-03 파마이센시아 코퍼레이션 펩티드-중합체 접합체
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
KR101813595B1 (ko) 2010-01-22 2017-12-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 장기적 생체 내 효능을 갖는 성장 호르몬
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
WO2016073825A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
US20190290733A1 (en) * 2015-03-11 2019-09-26 Nektar Therapeutics Conjugates of an il-7 moiety and a polymer
RU2738416C2 (ru) * 2015-09-18 2020-12-14 Юниверсити Оф Миязаки Длительно действующее производное адреномедуллина
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69638117D1 (de) * 1995-09-21 2010-03-04 Genentech Inc Varianten des menschlichen Wachstumshormons
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
IL144259A0 (en) * 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
ATE246202T1 (de) * 1999-01-29 2003-08-15 Hoffmann La Roche Gcsf konjugate
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子

Also Published As

Publication number Publication date
EA200700431A1 (ru) 2008-02-28
HRP20040448A2 (en) 2006-02-28
PL374354A1 (en) 2005-10-17
KR20070072924A (ko) 2007-07-06
CA2467731A1 (en) 2003-05-30
EA008505B1 (ru) 2007-06-29
BR0214451A (pt) 2006-05-30
TNSN04090A1 (fr) 2006-06-01
MXPA04004809A (es) 2004-08-11
MA27544A1 (fr) 2005-10-03
ZA200403907B (en) 2007-12-27
WO2003044056A2 (en) 2003-05-30
CN1608079A (zh) 2005-04-20
NO20042182L (no) 2004-08-11
JP2005525302A (ja) 2005-08-25
ECSP045114A (es) 2004-07-23
WO2003044056A3 (en) 2003-08-21
OA13063A (en) 2006-11-10
GEP20063860B (en) 2006-06-26
KR20050044858A (ko) 2005-05-13
CO5580794A2 (es) 2005-11-30
EA200400565A1 (ru) 2005-06-30
AP2004003050A0 (en) 2004-06-30
EP1453859A2 (en) 2004-09-08
JP2006321808A (ja) 2006-11-30
AU2002356990A1 (en) 2003-06-10
IL162031A0 (en) 2005-11-20
IS7268A (is) 2004-05-17
RS53104A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
IL162031A0 (en) Chemically-modified human growth hormone conjugates
AU2002342653A8 (en) Modified growth hormone
AU2003304235A1 (en) Chemically-modified human growth hormone conjugates
AU9175801A (en) Flexible implant
GB0100658D0 (en) Crystallisation - resistant aqueous growth hormone formulations
IL153067A0 (en) Growth hormone secretagogues
HUP0402496A3 (en) Growth hormone fusion protein
IL147253A0 (en) Growth hormone formulations
AU2001272974A1 (en) Human receptors
GB2411404B (en) Biologically active peptide conjugates
GB0119665D0 (en) Conjugates
GB0319495D0 (en) An implant
HUP0402334A3 (en) Modified human growth hormone
EP1385556A4 (en) PEPTIDE CONJUGATES WITH AFFINITY FOR GASTRIN RECEPTORS
GB0106565D0 (en) Growth hormone treatment
AU2002343197A8 (en) Biologically active complex
EP1373299A4 (en) Connective tissue GROWTH FACTOR-2
GB0111277D0 (en) Gentle marker
AU2002364314A8 (en) Growth hormone agonist peptides and their uses
GB2382347B (en) Hemoglobin conjugates
AU2001263350A1 (en) Peptides that stimulate mycobacterial growth
GB0408136D0 (en) A human G protein coupled receptor
GB0127214D0 (en) Growth hormone variations in humans an their uses
AU145153S (en) Implant
AU143439S (en) Curved crop lifter

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees